Four phase 3 trials were launched involving a total of 4,570 mild–moderate AD patients randomized to placebo and bapineuzumab.109 Two separate trials were conducted in APOE4 carriers and noncarriers predominantly in North America (ClinicalTrials.gov identifiers NCT00575055 and NCT00574132); 2 parallel trials were conducted predominantly in the rest of the world (NCT00667810 and NCT00676143). This evidence concerns the gene APOE and Alzheimer disease.